Key result
SαV-DAb nanovesicles improve LVEF and reduce myocardial fibrosis after ischemia-reperfusion in mice.
Why the study?
After acute myocardial infarction, ischemia/reperfusion injury and CD47/SIRPα-impaired efferocytosis sustain tissue damage, while the cardioprotective efficacy of endogenous plasma small extracellular vesicles is limited by low cardiac accumulation.
Does treatment with dual-antibody functionalized SIRPα-variant nanovesicles (SαV-DAb) improve cardiac systolic function, promote efferocytosis, and attenuate ventricular fibrosis compared to control nanovesicles or PBS in a mouse model of myocardial ischemia/reperfusion injury?
Does treatment with dual-antibody functionalized SIRPα-variant nanovesicles (SαV-DAb) improve cardiac systolic function, promote efferocytosis, and attenuate ventricular fibrosis compared to control nanovesicles or PBS in a mouse model of myocardial ischemia/reperfusion injury?
Answers are grounded in this paper and cite their sources.
Engineered SIRPα-overexpressing nanovesicles conjugated with anti-CD42b and anti-CD63 antibodies (SαV-DAb) effectively hitchhike on platelets and capture endogenous circulating extracellular vesicles to target ischemic myocardium, restoring efferocytosis, reducing fibrosis, and improving systolic function after myocardial ischemia/reperfusion injury in mice.
Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied Myocardial ischemia/reperfusion injury (acute myocardial infarction). SαV-DAb (SIRPα-variant-overexpressing nanovesicles functionalized with anti-CD42b and anti-CD63 antibodies via a ROS-cleavable linker) vs. PBS, SαV-IgG, or NV-DAb was evaluated on Left ventricular ejection fraction (LVEF), fractional shortening (LVFS), end-systolic volume (LVESV), and myocardial fibrosis (p=<0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: